Last $0.66 USD
Change Today -0.01 / -1.49%
Volume 253.7K
TTNP On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

titan pharmaceuticals inc (TTNP) Key Developments

Titan Pharmaceuticals Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 11:00 AM

Titan Pharmaceuticals Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 11:00 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Speakers: Sunil Bhonsle, Principal Executive Officer, President, Principal Financial Officer, Secretary and Director.

Titan Pharmaceuticals Inc. Presents at LD Micro Conference, Dec-04-2014 08:30 AM

Titan Pharmaceuticals Inc. Presents at LD Micro Conference, Dec-04-2014 08:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Sunil Bhonsle, Principal Executive Officer, President, Principal Financial Officer, Secretary and Director.

Titan Pharmaceuticals Inc. Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence

Titan Pharmaceuticals Inc. announced completion of enrollment in the ongoing Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year. The study, which is being sponsored and managed by Braeburn Pharmaceuticals, has randomized 178 patients across 21 centers. With a low screening failure rate and high patient interest, Braeburn successfully enrolled the entire study in a little over four months. The Probuphine clinical study in progress is a randomized, double-blind, double-dummy design that has enrolled patients in two parallel treatment arms. The study population is clinically stable patients who are receiving maintenance treatment with an FDA-approved sublingual formulation containing buprenorphine at a daily dose of 8mg or less. Patients have been randomized either to receive four Probuphine implants or to continue the daily sublingual buprenorphine therapy. The patients are expected to be treated for six months, and the primary analysis will be a non-inferiority comparison of responders in the two arms.

Titan Pharmaceuticals Inc. Reports Unaudited Earnings Results Third Quarter and Nine Months Ended September 30, 2014

Titan Pharmaceuticals Inc. reported unaudited earnings results third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue was $911,000 against $2,198,000 a year ago. Loss from operations was $738,000 against $128,000 a year ago. Net income and comprehensive income was $716,000 against loss of $1,145,000 a year ago. Diluted loss per share was $0.01 against loss of $0.01 per basic share a year ago. Revenue earned during the quarters ended Sept. 30, 2014 and 2013 reflects the amortization of the upfront license fee received from development and commercialization partner Braeburn Pharmaceuticals in December 2012. For the nine months, the company reported total revenue was $2,734,000 against $9,570,000 a year ago. Loss from operations was $2,222,000 against $249,000 a year ago. Net loss and comprehensive loss was $1,930,000 against income of $9,920,000 a year ago. Diluted loss per share was $0.03 against earnings of $0.11 per share a year ago.

Titan Pharmaceuticals, Inc. Announces Board Appointments

Titan Pharmaceuticals Inc. announced that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan. Mr. Akers brings to Titan extensive executive and financial experience. As president of Bayer's hematology/cardiology business, he oversaw the core of Bayer's specialty pharmaceuticals development, with significant products in hematology and specialty cardiology. Mr. Akers also served as president and CEO of Bayer Business and Corporate Services and held numerous other financial and executive positions during his 37-year career with the company. Mr. McNab, an entrepreneur experienced in building and growing companies, brings to Titan extensive corporate development experience. He is co-founder and chairman of Curis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTNP:US $0.66 USD -0.01

TTNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $70.80 USD -2.00
Reckitt Benckiser Group PLC 5,850 GBp +95.00
View Industry Companies
 

Industry Analysis

TTNP

Industry Average

Valuation TTNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.4x
Price/Book 17.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TITAN PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.